Skip to content
Medical Health Aged Care

OKRA.ai, an Envision Pharma Group Company, Appoints Dr. Yahya Anvar to Senior Leadership Position

Envision Pharma Group 3 mins read

PHILADELPHIA, PA / ACCESSWIRE / June 15, 2023 / OKRA.ai, an Envision Pharma Group (Envision) company, has appointed senior leader Dr. Yahya Anvar as Chief of AI Science & Insights to unleash the full potential of artificial intelligence (AI) and to further support the life sciences industry.

Envision Pharma Group, Thursday, June 15, 2023, Press release picture



"I am excited about continuing the innovative collaboration between Envision and OKRA.ai along with Yahya as a senior leader as it further solidifies our Envision commitment to the expansion of OKRA.ai and leadership in the AI and technical space," shares Meg Heim, CEO of Envision Pharma Group. "His leadership is critical to our vision to accelerate the delivery of our compelling combination of technology-enabled capabilities and solutions to clients as we continue to strengthen our offerings across the product life cycle, but more importantly to support patients in their journey to health and wellness."

Anvar joined OKRA.ai in 2019, heading the Data Science team. During his tenure, he has led the development of AI solutions across OKRA.ai's portfolio of products and services. Prior to joining the company, he served as the principal investigator of preclinical personalized medicine at Leiden University Medical Center. He has over 14 years of experience in the healthcare sector and is the author of over 30 peer-reviewed scientific articles. Anvar holds a PhD in Computational Biology from the faculty of Medicine at Leiden University, and an MSc in Bioinformatics and Artificial Intelligence from Brunel University.

Anvar shares, "It is an absolute privilege to be leading the AI insights and science at Envision and pushing the boundaries of what AI has to offer to better patients' outcomes. Making an impact through solutions that provide actionable, explainable insights is what we thrive for. There is no better time for new beginnings than today, and I'm so excited to be working with the Envision team to transform the industry as we know it."

Dr. Loubna Bouarfa, Head of AI & Innovative Platforms at Envision, shares, "It was a pleasure to work with Yahya; he has been an exceptional leader of the Data Science team at OKRA.ai. His role has now expanded to cover AI insights and scientific expertise across the entire Envision organization following our recent acquisition. I look forward to working with him in driving AI innovation and propelling Envision to new heights."

About Envision Pharma Group

Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 18 of the top 20 pharmaceutical companies. Envision supports clients across the product life cycle through a comprehensive suite of services and industry-leading technology solutions that include artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions. Learn more at www.envisionpharmagroup.com.

Contact Information:

Colleen Carter
Associate Director, Communications, Office of CEO
[email protected]
1 (508) 505 8856

SOURCE: Envision Pharma Group

.


View source version on accesswire.com:
https://www.accesswire.com/761331/OKRAai-an-Envision-Pharma-Group-Company-Appoints-Dr-Yahya-Anvar-to-Senior-Leadership-Position

More from this category

  • Medical Health Aged Care
  • 16/06/2026
  • 14:30
Dementia Australia

Brisbane comes together for people impacted by dementia

Brisbane community members tied up their laces and showed up in force last weekend for the 2026 Brisbane Memory Walk & Jog - throwing their support behind people impacted by dementia whilst getting active to improve their brain health. More than 1,470 people walked, ran and jogged to the finish line to raise an impressive total of $195,098. Dementia Australia CEO Professor Tanya Buchanan extended her gratitude to all who participated, volunteered and raised vital funds for the cause. “There was an incredible turnout from the Brisbane community this year yet again, in support of the many people impacted by…

  • Contains:
  • Biotechnology, Medical Health Aged Care
  • 16/06/2026
  • 09:51
ENA Respiratory

ENA Respiratory Receives USPTO Notice of Allowance for Two Patents Covering TLR2 Agonists and Rhinovirus-Mediated COPD Exacerbations

Melbourne, Australia, 15 June 2026 – ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, announces today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for two patent applications notably a composition-of-matter patent and method-of-use for its Toll-like receptor 2 (TLR2) therapies. A composition-of-matter patent (US 17/622,451, "A series of TLR2 agonist compounds") and A method-of-use patent for the treatment of rhinovirus-mediated exacerbations of chronic obstructive pulmonary disease (COPD) (US 16/495,829, "Methods of treating rhinovirus-mediated exacerbations of COPD…

  • Medical Health Aged Care
  • 16/06/2026
  • 08:35
Neuroscience Research Australia (NeuRA)

Review provides latest evidence on low back pain assessment and treatment

Key Facts: · Latest evidence on low back pain finds most patients don’t need scans, surgery or strong medicines. · Researchers from Neuroscience Research Australia (NeuRA), UNSW Sydney and the US worked on the review of hundreds of studies to provide clinicians with an up-to-date guide to the assessment and management of low back pain. · It’s hoped the review will provide practical guidance for clinical care and assist patients in receiving tests and treatments that work.Low back pain affects around 619 million people worldwide, but a new review suggests many are receiving unnecessary scans and ineffectual treatments. Researchers compiled…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.